Skip to main content
GameRevenueData

Developer

The Chinese Room Games: Revenue & Sales Estimates

Revenue estimates for the 6 Steam games developed by The Chinese Room, ranked by estimated net revenue. Available estimated lifetime net (USD): $31.3M.

Catalog Est. Lifetime Net (USD)

$31.3M

Estimates for 6 of 6 tracked games

Tracked games

6

Top Earner

Vampire: The Masquerade® - Bloodlines™ 2

$16M

Coverage: 6 tracked titles; 6 with net estimates; 0 without. 6 have dedicated profiles. Missing estimates are excluded from the aggregate, not treated as known zero revenue.

Role: Developer. These are lifetime estimates for games credited to The Chinese Room; they are not company earnings, profit, or contractual receipts. Credits may omit co-development or historical publishing arrangements. Developer and publisher identities are not merged by matching names.

Recorded release dates: 2013-09-10–2025-10-21 (may include announced dates).

Largest title accounts for 51.2% of available estimated net revenue. Coverage gaps can change this share.

Showing 1–6 of the top 6 displayed entries, from 6 tracked titles. Figures include only available estimates. Search the full catalog .

Rows 1–6 · Page 1 of 1

# Game Est. lifetime net (USD) Positive reviews (raw) Release
1 Vampire: The Masquerade® - Bloodlines™ 2 $16M 56%Mixed (11.6K) Oct 21, 2025
2 Still Wakes the Deep $8M 88%Positive (10.6K) Jun 18, 2024
3 Amnesia: A Machine for Pigs $5M 70%Positive (11.8K) Sep 10, 2013
4 Dear Esther: Landmark Edition $1.3M 75%Positive (7.2K) Feb 14, 2017
5 Everybody's Gone to the Rapture $748.7K 68%Mixed (2.1K) Apr 14, 2016
6 Little Orpheus $188K 67%Mixed (620) Sep 13, 2022

Get real-time dashboards, historical trends, and AI-powered analysis

Explore on PlayRev(opens in new tab)

Revenue and sales estimates are based on the Boxleiter method using publicly available data including Steam review counts, pricing history, and statistical modeling. Actual revenue may differ significantly. These figures are provided for informational purposes only and should not be used for financial decisions. Read the full methodology.